FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

3.1 , I I I

OMB APPROVAL								
OMB Number:	3235-02							

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SACHS BRUCE I (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					3. D	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 02/20/2014									all app Direc	olicable) etor er (give title	ing Person(s) to Issuer 10% Owner Other (specify below)		wner (specify
(Street) BOSTON (City)	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person								
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N						2A. Deemed Execution Date, (fear) if any		a. Transaction Code (Instr.			Acquire	d (A) or	5. Amount of Securities Beneficially		ount of ities icially	6. Ownership Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial	
			(Month/Day/Year)			8) Code	v	Amount	mount (A) or (D)		Rep Tran		d Following ted action(s) 3 and 4)	(I) (Instr. 4		Ownership (Instr. 4)			
Common Common	014			S ⁽¹⁾		1,300 3,800	D D	\$82.5			36,910 33,110	D D	_						
Common Stock 02/20/2									S ⁽¹⁾		3,200	D	\$84.1			29,910			
1. Title of Derivative Security (Instr. 3)	Title of 2. Serivative conversion lecurity or Exercise (Month/Day/Year) (e.g.			(e.g., po	uts, c 4. Transa	saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		uired, Disposed of, , options, convertib 6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration					8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Owner Form: Direct or Indi (I) (Ins	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$82.51 (range \$82.00 to \$82.99).
- 3. Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$83.65 (range \$83.16 to \$83.99).
- 5. Open market sales reported on this line occurred at a weighted average price of \$84.13 (range \$84.02 to \$84.35).

Remarks:

Kenneth L. Horton, Attorney-In-Fact

02/24/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.